1.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181202, NCT01525550
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001K24133E1, NCT01595009
|
|
3.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-2247, NCT00442533
|
|
4.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NU 11I03, NCI-2011-02939, STU00053541, NCT01465659
|
|
5.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRCA-CCTC-NET-01, EUDRACT-2004-005202-71, EU-207102, ISRCTN35124268, NCT00602082
|
|
6.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: AAAB3348, NCT00869050
|
|
7.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230D2203, 2008-007348-32, NCT00958841
|
|
8.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC0845, MC0845, 8233, NCT01010126
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: MAW002, NCT00978211
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-09-090, NCT01099540
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: EudraCT 2006-004748-22, NCT01203306
|
|
12.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070145, 2007-005628-34, NCT01215578
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 78,256, NCT01237457
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16438, CSOM230DUS23T, NCT01253161
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230I2201, 2010-023183-40, NCT01374451
|
|
16.
|
Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 11-274, NCT01466036
|
|
17.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: END0012, NCI-2011-03497, SU-10282011-8571, NCT01525082
|
|
18.
|
Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBEZ235Z2401, 2012-000769-19, NCT01628913
|
|
19.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HE 67/12, 2011-006160-48, NCT01648465
|
|
20.
|
Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBEZ235F2201, 2012-000675-16, NCT01658436
|
|
21.
|
Phase: Phase I Type: Treatment Status: Active Age: 2 to 25 Sponsor: NCI Protocol IDs: UIHC-200008086, NCI-V02-1710, NCT00049023, 200008086
|
|
22.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MDA-2009-0734, 2009-0734, 8354, NCT01204476
|
|
23.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230F2102, 2010-018895-26, NCT01263353
|
|
24.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 16866B, NCT01342354
|
|
25.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230D2101, NCT01364415
|